Helsinn/Eisai’s Anti-Nausea Combo Akynzeo Could Boost NK-1 Class
Helsinn and Eisai’s Akynzeo combines two different targets in one oral tablet for chemotherapy-induced nausea and vomiting – the marketed 5-HT3 antagonist Aloxi (palonosetron) and the new entity netupitant, a member of the underused NK-1 inhibitor class.
You may also be interested in...
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.
Patients with the most severe type of disease were all randomized to treatment with the study drug, which may have had a negative impact on outcome, the Israeli company suggested.